Gastrointestinal Cancer

In an 8 to 5 vote, ODAC voted in support of launching 2 single-arm trials seeking to characterize the risk-benefit profile of dostarlimab for patients with dMMR/MSI-H locally advanced rectal cancer.

Zev A. Wainberg, MD, discusses the implications of the findings from the phase 3 NAPOLI 3 trial for patients with metastatic pancreatic ductal adenocarcinoma.

A study in the Oncology Nursing Forum highlights which factors are associated with positive psychology and symptom burden in colorectal cancer survivors.

Patients with RAS-wild-type metastatic colorectal cancer did not experience a benefit in terms of response rate or survival when cetuximab was added to the first cycle of chemotherapy.

Nanvuranlat inspired better progression-free survival in patients with advanced, pretreated refractory biliary tract cancer, meeting the primary end point of a phase 2 trial.

Newer agents approved for frontline hepatocellular carcinoma, including lenvatinib, and atezolizumab/bevacizumab, yielded superior survival outcomes than sorafenib in a real-world setting.

Neoadjuvant pembrolizumab elicited high clinical activity in patients with mismatch repair deficiency/microsatellite instability high solid tumors and was well tolerated.

Patients with hepatocellular carcinoma experienced better health-related quality of life outcomes with tislelizumab vs sorafenib.

Encorafenib plus cetuximab, along with chemotherapy, was linked to antitumor activity and a manageable safety profile in patients with BRAF V600E-mutant metastatic colorectal cancer.

Neoadjuvant chemoradiation followed by pancreaticoduodenectomy resulted in 0.14 more quality-of-life years than upfront surgery followed by adjuvant chemotherapy in patients with resectable pancreatic cancer.

Findings from the phase 3 SUNLIGHT study showed that adding bevacizumab to trifluridine/tipiracil boosted overall survival in metastatic colorectal cancer.

The median overall survival with frontline liposomal irinotecan/NALIRIFOX was 11.1 months vs 9.2 months with nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.

The median overall survival with nivolumab plus chemotherapy was 12.8 months, vs 10.7 months with chemotherapy alone, in patients with treatment-naïve advanced esophageal squamous cell carcinoma.

An analysis of 141 children who had prenatal exposure to maternal cancer showed promising cognitive and behavioral functions at age 9 years.

Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.

For patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, treatment with zolbetuximab/mFOLFOX6 yielded a progression-free survival (PFS) of 10.61 months whereas placebo/mFOLFOX6 resulted in a PFS of 8.67 months.

In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.

Patients with advanced hepatocellular carcinoma experienced similar health-related quality of life scores whether they received a combination of pembrolizumab and lenvatinib or lenvatinib and placebo.

The FDA has granted accelerated approval to tucatinib and trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer. The prescribing information includes warnings for diarrhea and hepatotoxicity.

At a median follow-up of 40 months, patients with unresectable, progressive neuroendocrine pancreatic tumors achieved an 80% progression-free survival rate with Lutathera.

The American Society of Clinical Oncology (ASCO) has released new guidelines providing recommendations for the optimal treatment of patients with advanced gastroesophageal cancer.

Adjuvant treatment with hepatic arterial infusion chemotherapy-infused FOLFOX improved disease-free survival rates for patients with hepatocellular carcinoma with microvascular invasion.

A combined regimen of mitazalimab and mFOLFIRINOX resulted in a 52% objective response rate among 23 patients with metastatic pancreatic cancer.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The FDA has approved updated labeling for capecitabine under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs.